Lipid levels appeared to be lower after treatment with PCSK9 inhibitors, indicating that this type of dyslipidemia treatment may be a safe choice for managing the cardiovascular risk in these patients [12, 13, 15, 17]. Here, PCSK9 is linked to metabolic syndrome.